## Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease

Matthew J. Johnson<sup>123</sup>, Kanut Laoharawee<sup>123</sup>, Walker S. Lahr<sup>123</sup>, Beau R. Webber<sup>123</sup>, Branden S. Moriarity<sup>123\*</sup>

<sup>1</sup>Department of Pediatrics, University of Minnesota, Minneapolis MN 55455, USA; <sup>2</sup>Center for Genomic Engineering, University of Minnesota, Minneapolis MN 55455, USA; <sup>3</sup>Masonic Cancer Center, University of Minnesota, Minneapolis MN 55455

\*Corresponding Author: Branden S. Moriarity, Cancer and Cardiovascular Research Building, 2231 6<sup>th</sup> St. SE, University of Minnesota, Minneapolis, MN 55455, USA. Ph: +612 625 2226; Email: mori0164@umn.edu



B cell subsets in the peripheral blood

Gating scheme used for the identification of B cell subsets by flow cytometry.

## Supplementary Figure 2





Percent indel formation with two different gRNAs targeting BCL2.

## Supplementary Table 1

Specificity	Fluorophore	Clone	Vendor
CD10	BV711	HI10a	Biolegend
CD19	BUV395	SJ25C1	BD Horizon
CD20	PE/Dazzle 594	HIT2	Biolegend
CD21	BV650	B-ly4	BD OptiBuild
CD27	BV605	O323	Biolegend
CD38	BUV496	HIT2	BD Horizon
CD138	BV510	MI15	Biolegend
CXCR5	BV421	RF8B2	BD Horizon
lgD	PE	IA6-2	<b>BD</b> Pharmingen
lgG	APC	M1310G05	Biolegend
IgM	PE-Cy7	MHM-88	Biolegend

## Flow cytometry antibodies

List of antibodies used for flow cytometry in this study

Unmodified, full-sized images of gels used to construct Figures 5C and 6C.



Figure 5C *left panel* 



Figure 5C central panel



Figure 5C right panel



Figure 6C